Effect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1

ABSTRACT: Cultured cell line UCSD-AML1 (45,XX,-7,t(3;3)(q21;q26)) and patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 100 nM of FHD-286 for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a small molecule, chromatin remodeling complex protein, dual SMARCA2/SMARCA4 enzymatic activity inhibitor in MECOM rearranged AML cells with EVI1 overexpression. We also compared the global expression changes that were common between the two FHD-286-treated AML subtypes.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Antrix Jain  

LAB HEAD: Kapil Bhalla

PROVIDER: PXD059060 | Pride | 2026-01-23

REPOSITORIES: Pride